Peripherally-restricted dopamine agonist but not norepinephrine uptake inhibitor alters prolactin release

2012 ◽  
Vol 66 (2) ◽  
pp. 203-204
Author(s):  
Lewis B. Kinter ◽  
Jen Venzie ◽  
Pam Campbell ◽  
Patricia Bentley ◽  
Hakan Andersson ◽  
...  
2005 ◽  
Vol 182 (3) ◽  
pp. 400-413 ◽  
Author(s):  
Inés Artaiz ◽  
Arturo Zazpe ◽  
Ana Innerárity ◽  
Elena del Olmo ◽  
Alvaro Díaz ◽  
...  

2004 ◽  
Vol 127 (1-2) ◽  
pp. 115-120 ◽  
Author(s):  
Manuela Di Benedetto ◽  
Denise Feliciani ◽  
Claudio D'Addario ◽  
Sari Izenwasser ◽  
Sanzio Candeletti ◽  
...  

1992 ◽  
Vol 160 (3) ◽  
pp. 372-378 ◽  
Author(s):  
I. M. Anderson ◽  
C. J. Ware ◽  
J. M. da Roza Davis ◽  
P. J. Cowen

The prolactin response to intravenous clomipramine, a 5-HT uptake inhibitor, was significantly attenuated in 12 patients with major depression. In contrast, in a further 12 depressed patients, the PRL responses to thyrotropin-releasing hormone, which acts directly on the pituitary to release PRL, were not reduced. These findings suggest that the reduction in 5-HT-mediated PRL release seen in depressed patients is due to an impairment of brain 5-HT function rather than a pituitary abnormality.


1978 ◽  
Vol 87 (1) ◽  
pp. 12-18 ◽  
Author(s):  
Wayne Leebaw ◽  
Louyse Lee ◽  
Paul Woolf

ABSTRACT Lergotrile mesylate, an ergot derivative and dopamine agonist, decreases basal (single sample) prolactin levels and blunts phenothiazine-mediated prolactin release. To more thoroughly evaluate the effect of this drug, we measured prolactin and growth hormone concentrations hourly over 24 h in 5 healthy women and during insulin (0.1 U/kg) induced hypoglycaemia (ITT) in 6 women before and during 2-day lergotrile treatment. Lergotrile (4.0 to 6.0 mg/day) significantly decreased the mean 24-hour prolactin concentration in 3 and abolished the nocturnal rise in 4. For the entire group, the mean nocturnal levels (2400–0700 hours) were 24.0 #x00B1;7.5 vs 14.4 ± 3.9 ng/ml during waking (0800–2300 hours) pre-lergotrile (P<0.05), while during therapy the concentrations were 8.9 ± 2.8 vs 8.0 ± 1.4 ng/ml (NS), respectively. The prolactin response to ITT was also significantly inhibited by lergotrile with the peak response reduced from 78.2 ± 35.1 ng/ml to 9.0 ± 3.6 ng/ml (P < 0.05). The mean 24-hour growth hormone concentration was unchanged during therapy, and there was no significant effect on the GH response during ITT. The effects of chronic therapy with lergotrile (8 mg/day for 6 weeks) were studied in one acromegalic patient with elevated levels of prolactin and growth hormone. Her prolactin concentration fell from 452.2 ± 8.0 to 216 ng/ml, while GH declined from 23.8 ± 1.3 to 14.8 ng/ml. Lergotrile mesylate effectively lowers mean 24-hour prolactin concentrations (determined hourly) and completely abolishes both nocturnal and hypoglycaemia-mediated prolactin release. This drug may also be beneficial in the therapy of acromegaly.


2013 ◽  
Author(s):  
Brad D. Miller ◽  
Lauren A. Marks ◽  
Jonathan Koller ◽  
Blake J. Newman ◽  
G. Larry Bretthorst ◽  
...  

Background: This study’s goal was to provide dose-response data for a dopamine agonist in the baboon using standard methods (replicate measurements at each dose, across a range of doses), as a standard against which to subsequently validate a novel pharmacological MRI (phMRI) method. Dependent variables were functional MRI (fMRI) data from brain regions selected a priori, and systemic prolactin release. Necessary first steps included estimating the magnitude and time course of prolactin response to anesthesia alone and to various doses of agonist. These first steps (“time course studies”) were performed with three agonists, and the results were used to select promising agonists and to guide design details for the single-dose studies needed to generate dose-response curves. Methods: We studied 6 male baboons (Papio anubis) under low-dose isoflurane anesthesia after i.m. ketamine. Time course studies charted the changes in plasma prolactin levels over time after anesthesia alone or after an intravenous (i.v.) dose of the dopamine D1-like agonists SKF82958 and SKF38393 or the D2-like agonist pramipexole. In the single-dose dopamine agonist studies, one dose of SKF38393 (ranging from 0.0928 – 9.28 mg/kg, N=5 animals) or pramipexole (0.00928 – 0.2 mg/kg, N=1) was given i.v. during a 40-minute blood oxygen level dependent (BOLD) fMRI session, to determine BOLD and plasma prolactin responses to different drug concentrations. BOLD response was quantified as the area under the time-signal curve for the first 15 minutes after the start of the drug infusion, compared to the linearly predicted signal from the baseline data before drug. The ED50(estimated dose that produces 50% of the maximal possible response to drug) for SKF38393 was calculated for the serum prolactin response and for phMRI responses in hypothalamus, pituitary, striatum and midbrain. Results: Prolactin rose 2.4- to 12-fold with anesthesia alone, peaking around 50-90 minutes after ketamine administration and gradually tapering off but still remaining higher than baseline on isoflurane 3-5 hours after ketamine. Baseline prolactin level increased with age. SKF82958 0.1mg/kg i.v. produced no noticeable change in plasma prolactin concentration. SKF38393 produced a substantial increase in prolactin release that peaked at around 20-30 minutes and declined to pre-drug levels in about an hour. Pramipexole quickly reduced prolactin levels below baseline, reaching a nadir 2-3 hours after infusion. SKF38393 produced clear, dose-responsive BOLD signal changes, and across the four regions, ED50 was estimated at 1.6-7.7mg/kg. Conclusions: In the baboon, the dopamine D1receptor agonist SKF38393 produces clear plasma prolactin and phMRI dose-response curves. Variability in age and a modest sample size limit the precision of the conclusions.


Sign in / Sign up

Export Citation Format

Share Document